saRNA Injection Targets Cardiac Injury
Preclinical study shows saRNA therapy improved cardiac function and reduced infarct size after myocardial infarction
Objective:
To develop a self-amplifying RNA (saRNA) therapy for supporting heart recovery post-myocardial infarction.
Key Findings:
- A single injection produced the hormone for over 4 weeks.
- Improved cardiac function, reduced infarct size, and less fibrosis were observed in preclinical models.
- The therapy was effective even in models with diabetes and atherosclerosis.
Interpretation:
The saRNA therapy may enhance the heart's natural healing processes and provide prolonged support after injury.
Limitations:
- Further studies on safety, timing, and dosing are needed before human trials.
Conclusion:
The approach offers a promising, less invasive alternative for cardiac recovery, potentially changing patient recovery trajectories.
